drugset / Trial / NCT00602511
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of the study is to compare thalidomide + dexamethasone with bortezomib + dexamethasone in patients with multiple myeloma refractory to melphalan therapy. The main goal is to find out which of these two 2:nd line regimens that offers the patients the best chance for a response with as long duration and as good quality of life as possible.
Timeline
- Start
- 2007-10
- Primary completion
- 2010-09
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Thalidomide | Other / unclassified | 200 mg | — |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |